Celsion Corporation (CLSN)
Chart Events
Performance Outlook
| Previous Close | 1.9900 |
| Open | 2.0500 |
| Bid | 1.9300 x 1100 |
| Ask | 1.9200 x 1400 |
| Day's Range | 1.9000 - 2.0807 |
| 52 Week Range | 1.8000 - 20.2500 |
| Volume | |
| Avg. Volume | 328,640 |
| Market Cap | 164.46M |
| Beta (5Y Monthly) | 2.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Benzinga
Celsion's Formulated DNA Plasmid COVID-19 Vaccine Candidate Shows Activity Against Two Strains
Celsion Corporation (NASDAQ: CLSN) has presented its PLACCINE platform technology at the World Vaccine Congress. "PLACCINE is demonstrating the potential to be a powerful platform that provides for rapid design capability for targeting two or more different variants of a single virus in one vaccine," said Dr. Khursheed Anwer, Chief Science Officer at Celsion. " Dr. Anwer continued, "In the murine model, our multivalent vaccine targeted against two different variants showed to be immunogenic as d
- Benzinga
3 Penny Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. U.S. Energy The Trade: U
- Zacks
Celsion (CLSN) COVID Vaccine Effective in Pre-Clinical Studies
Celsion (CLSN) announces data from pre-clinical studies for its investigational vaccine platform as a potential treatment for COVID-19.
